KIF4A was first reported in relation to X-linked recessive complex neurodevelopmental disorder with or without congenital anomalies in 2014 (Willemsen et al., PMID: 24812067). Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we determined two distinct disease entities, as KIF4A was also reported in relation to the disease taurodontism, microdontia, and dens invaginatus. In Kalantari et al., 2021 (PMID:34346154), two male siblings (Patient 7 & Patient 8) with taurodontism, microdontia, and dens invaginatus were reported. Neither manifested developmental delay/intellectual disability. While future evidence may elucidate a spectrum which includes probands with teeth abnormalities and without neurodevelopmental presentations, with our current understanding of the disease, they have not been included in this curation at this time. Therefore, the two disease entities have been split and this curation summarizes the gene-disease relationship between KIF4A and X-linked recessive complex neurodevelopmental disorder with or without congenital anomalies (MONDO: 0100465).
Affected individuals present with a variety of clinical features, including developmental delay/intellectual disability, seizures, bilateral cystic dysplastic kidneys, brain anomalies, and other congenital anomalies. Specific brain anomalies include hydrocephalus and agenesis of the corpus callosum. Ten variants (missense and in-frame indel) that have been reported in 15 probands across 3 publications (PMIDs: 24812067, 34346154, 30679815) are included in this curation. The mechanism of pathogenicity appears to be loss-of-function.
This gene-disease relationship is also supported by experimental evidence. Kif4a knockdown in rat models using siRNA was shown to alter the balance between excitatory and inhibitory synaptic input. Specifically, knockdown using kif4a-targeting siRNA led to significant decrease in mEPSC amplitude, but an increase in mEPSC frequency compared to control siRNA, as well as significant decrease in mIPSC frequency (PMID: 24812067). There was also altered kif4a RNA expression levels in affected patients compared to relative controls, cDNA sequencing showing alternate splicing, and FFPE brain tissue qPCR which showed significant decrease in KIF4A levels in affected patients compared to age-matched controls (PMIDs: 34346154, 30679815).
In summary, there is limited evidence to support the relationship between KIF4A and complex neurodevelopmental disorder with or without congenital anomalies. Although more evidence is needed to support a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship. This classification was approved by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel on April 11, 2024 (SOP Version 10).
The GenCC data are available free of restriction under a CC0 1.0 Universal (CC0 1.0) Public Domain Dedication. The GenCC requests that you give attribution to GenCC and the contributing sources whenever possible and appropriate. The accepted Flagship manuscript is now available from Genetics in Medicine (https://www.gimjournal.org/article/S1098-3600(22)00746-8/fulltext).
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. The GenCC does not independently verify the submitted information. Though the information is obtained from sources believed to be reliable, no warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, reliability or usefulness of any information. This disclaimer applies to both isolated and aggregate uses of the information. The information is provided on an "as is" basis, collected through periodic submission and therefore may not represent the most up-to-date information from the submitters. If you have questions about the medical relevance of information contained on this website, please see a healthcare professional; if you have questions about specific gene-disease claims, please contact the relevant sources; and if you have questions about the representation of the data on this website, please contact gencc@thegencc.org.